{"disease":{"id":"x-linked-hypophosphatemia","name":"x linked hypophosphatemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03193476","title":"Registry for Patients With X-Linked Hypophosphatemia","phase":"","overall_status":"RECRUITING","enrollment_count":1343,"lead_sponsor_name":"Kyowa Kirin Pharmaceutical Development Ltd","has_results":false},{"nct_id":"NCT03745521","title":"Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT02526160","title":"Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT07183579","title":"Effective Dosing of Burosumab in XLH","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03820518","title":"Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04273490","title":"Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06921720","title":"Phosphorus-31 Spectroscopy in Phosphate Diabetes","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02915705","title":"Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT04872907","title":"Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04419363","title":"Burosumab in Children and Adolescents With X-linked Hypophosphatemia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Bicetre Hospital","has_results":false},{"nct_id":"NCT02163577","title":"Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT03596554","title":"X-linked Hypophosphatemia and FGF21","phase":"","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04695860","title":"Anti-FGF23 (Burosumab) in Adult Patients With XLH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Wuerzburg University Hospital","has_results":false},{"nct_id":"NCT03879915","title":"Dental Implants in Patients With X-linked Hypophosphatemia","phase":"","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03920072","title":"Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Kyowa Kirin Pharmaceutical Development Ltd","has_results":false},{"nct_id":"NCT04842032","title":"Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT06067932","title":"Foot Disorders in X-linked Hypophosphatemia","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Orthopedic Hospital Vienna Speising","has_results":false},{"nct_id":"NCT05181839","title":"A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Kyowa Kirin Pharmaceutical Development Ltd","has_results":false},{"nct_id":"NCT06525636","title":"A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT02312687","title":"Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT04842019","title":"Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT04188964","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Kyowa Kirin Pharmaceutical Development Ltd","has_results":false},{"nct_id":"NCT02537431","title":"Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT02750618","title":"Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Kyowa Kirin, Inc.","has_results":true},{"nct_id":"NCT04049877","title":"Retrospective and Prospective Disease Progression and Quality of Life in XLH","phase":"","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Medialis Ltd.","has_results":false},{"nct_id":"NCT04146935","title":"Examining the Effect of Burosumab on Muscle Function","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT03489993","title":"FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)","phase":"","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT03775187","title":"Expanded Access to Burosumab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}